The U.S. Food and Drug Administration today said Baxter International Inc. needs to take several steps designed to follow through on a recall of its Colleague infusion pumps including providing customers with a “a refund, a replacement pump, or lease termination.” Get the full story »
Inside these posts: Colleague pumps
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
S&P lowers Baxter outlook but maintains ratings
Associated Press | Standard & Poor’s Ratings Services reduced
its outlook on Baxter International Inc. Thursday, but said Baxter’s
diverse range of products will help it deal with a recall of its drug
infusion pumps.
Standard & Poor’s said its view of Baxter’s credit is “Stable,” down
from a previous “Positive” outlook. The firm maintained its
investment-grade “A+” corporate credit rating on the company.
